Cover Page

Cite item


It was currently shown that hepatopathy due to drug toxicity is associated with increased apoptosis of hepatocytes. Therefore, development of drugs which regulate cell death is of great importance. Aim: to involve some hepatoprotectors (ademethionine, reamberin, remaxol) and immunomodulators (cycloferon) into regulation of apoptosis in experimental models of liver first-line antituberculousis drugs (isoniazid, rifampicin, pyrazinamide). Materials and methods: levels of apoptosis (TUNEL), expression of CD95 (receptor of tumor necrosis factor ― by immunohistochemistry), expression of caspase-8, caspase-3 and p53 (Western-blotting) were measured. Results: exposition of first-line antituberculousis drugs leads to dysthrophia of liver parenchyma cells with increased apoptosis of hepatocytes and activation of CD95, caspase-8 (external way) and overexpression of p53 and caspase-3. It was found that reamberin, cycloferon and remaxol have hepatoprotective effect improving liver histology; ademethionine administered by intraperitoneal injection showed no positive effects. Reamberin demonstrated apoptosis-inhibiting effect in the experiment whereas other drugs were found to be apoptosis inductors for hepatocytes in toxic hepatopathy. Conclusions: regulation of apoptosis by cycloferon and remaxol mediated by external and p53-dependent pathway is confirmed by increased expression of CD95 and p53 protein. Ademethionine might induce apoptosis by the intrinsic pathway.


About the authors

D. S. Sukhanov

Sechenov Institute of Evolutionary Physiology and Biochemistry, St. Petersburg, Russian Federation

Author for correspondence.
MD, associate professor of the Department of Phthisiopulmonology and Thoracic Surgery, I.I. Mechnikov North-Western State Medical University. Address: St. Petersburg, Kirochnaya Street, 41; tel.: (812) 303-50-00 Russian Federation

E. D. Bazhanova

Mechnikov Northwest Medical University, St. Petersburg, Russian Federation

PhD, leading research scientist of the Laboratory of Comparative Somnology and Neuroendocrinology, I. M. Sechenov Institute of Evolutionary Physiology and Biochemistry of RAS. Address: 194223, St. Petersburg, Thorez avenue, 44; tel.: (812) 552-32-27 Russian Federation

D. L. Teplyi

Аstrakhan State University, Russian Federation

PhD, professor, member of RANS, Head of the Department of Animal and Human Morphology and Physiology of Astrakhan State University. Address: 414040, Astrakhan, Tatishchev Street, 20a; tel.: (8512) 22-93-47 Russian Federation


  1. Balasubramanian A., Munshi N., Koziel M.J. Hu Z., Liang T.J., Groopman J.E., Ganju R.K. Structural proteins of hepatitis С virus induce interleukin 8 production and apoptosis in human endothelial cells. J. Gen. Virol. 2005; 86: 3291–3301.
  2. Kuo C.Y., Chou T.Y., Chen C.M., Tsai Y.F., Hwang G.Y., Hwang T.L. Hepatitis B virus X protein disrupts stress fiber formation and triggers apoptosis. Virus Res. 2013; 175 (1): 20–29.
  3. Morio Y., Tsuji M., Inagaki M., Nakagawa M., Asaka Y., Oyamada H., Furuya K., Oguchi K. Ethanol-induced apoptosis in human liver adenocarcinoma cells (SK-Hep1): Fas- and mitochondria-mediated pathways and interaction with MAPK signaling system. Toxicol. In Vitro. 2013; 27 (6): 1820–1829.
  4. Miao H.L., Pan Z.J., Lei C.J., Wen J.Y., Li M.Y., Liu Z.K., Qiu Z.D., Lin M.Z., Chen N.P., Chen M. Knockdown of GPC3 inhibits the proliferation of Huh7 hepatocellular carcinoma cells through down-regulation of YAP. J. Cell Biochem. 2013; 114 (3): 625–631.
  5. Ghavami S., Hashemi M., Kadkhoda K., Alavian S.M., Bay G.H., Los M. Apoptosis in liver diseases — detection and therapeutic applications. Med. Sci. Monit. 2005; 11 (11): 3337–3345.
  6. An J., Mehrhof F., Harms C., Lättig-Tünnemann G., Lee S.L., Endres M., Li M., Sellge G., Mandić A.D., Trautwein C., Donath S. ARC is a novel therapeutic approach against acetaminophen-induced hepatocellular necrosis. J. Hepatol. 2013; 58 (2) : 297-305.
  7. Bol'f S.B., Sukhanov D.S., Romantsov M.G. Drug-induced liver damage in chemotherapy of tuberculosis. Vestn. S.Pb. Gos. med. akad. I.I. Mechnikova - Bulletin of the St. Petersburg Medical Academy of Postgraduate Education named after I. Mechnikov. 2009; 1: 172–176.
  8. Slivka Yu.I. Comparative characteristics of hepatotoxicity of isoniazid, rifampicin and pyrazinamide. Farmakol. i toksikol. = Pharmacology and Toxicology. 1989; 4: 82–85.
  9. Zeits G. Alcoholic liver disease. Ross. zhurn. gastroent. gepatol. Koloproktol = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2001; 4: 62–65.
  10. García-Vaquero M., Benedito J.L., López-Alonso M., Miranda M. Histochemistry evaluation of the oxidative stress and the antioxidant status in Cu-supplemented cattle. Animal. 2012; 6 (9): 1435–1443.
  11. Lu Y., Chen G.Q. Effector caspases and leukemia. Int. J. Cell Biol. 2011; 738301. doi: 10.1155/2011/738301.
  12. Bazhanova E.D. Cycloferon: mechanism of action, functions and application. Zhurn. eksperim. i klinich. farmakol = Journal of Experimental and Clinical Pharmacology. 2012; 75 (7): 40–44.
  13. Shevyreva E.V., Ivanov A.K., Sukhanov D.S., Murzina A.A. Remaxol hepatoprotective therapy in patients with tuberculosis and HIV infection in day hospital of tuberculosis dispensary. Antibiotiki i khimioterapiya - Antibiotics and Chemotherapy. 2012; 7 (8): 31–37.
  14. Lee E.S., Chen H., Hardman C., Simm A., Charlton C. Excessive S-adenosyl-L-methionine-dependent methylation increases levels of methanol, formaldehyde and formic acid in rat brain striatal homogenates: possible role in S-adenosyl-L-methionine-induced Parkinson's disease-like disorders. Life Sci. 2008; 83 (25–26): 821–827.

Copyright (c) 1970 "Paediatrician" Publishers LLC

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies